

Brussels, 10 February 2016 (OR. en)

5940/16

JAI 84 CORDROGUE 8 SAN 42

#### **OUTCOME OF PROCEEDINGS**

From: General Secretariat of the Council

On: 25 January 2016

To: Delegations

Subject: Summary of discussions

### 1. Adoption of the agenda

The meeting adopted the agenda as outlined in doc. CM 1192/16 with the addition of the following AOB point: "Forthcoming elections of the members of the INCB".

### 2. Preparation for UNGASS 2016

Presentation by the representative of UNAIDS on the priorities for UNGASS 2016

The representative of UNAIDS gave an overview of HIV infections among people injecting drugs, informing the meeting that globally out of 12.7 million people who injected drugs, 1.7 million (13.1%) were estimated to be living with HIV and that the highest HIV prevalence rates were detected in South West Asia (28.8%) and Eastern/South Eastern Europe (23.0%). The speaker explained that people who injected drugs were being left behind in responses mainly because of criminalization and punitive laws, as 56–90% of them tended to be incarcerated at some stage during their life, absence or inadequacy of prevention services, widespread societal stigma and lack of investment.

The speaker stressed that HIV service coverage was generally low, particularly with regard to the priority interventions such as needle and syringe programmes and opioid substitution therapy with only around 10 % of people who injected drugs having access to needle and syringe programmes and 8% to opioid substitution therapy. She put forward a number of actions to be taken so as to address the problem in a more efficient way, including recognising that the main purpose of drug control was to ensure health, well-being and security of individuals and committing to fully implement harm reduction and HIV services.

The Presidency expressed strong EU support for the call for full implementation of harm reduction measures.

# Outcomes of the informal CND meetings on the UNGASS outcome document held in January and preparation for the 1st intersessional meeting of the 59th CND session

The Presidency reported on the outcomes of the informal CND meetings held in January 2016 before the 1st CND intersessional meeting, notably the discussions on flexibility within the UN Drugs Convention, the role of civil society, inclusion of other UN bodies, especially WHO, risk and harm reduction measures. Delegations prepared for the 1st CND intersessional meeting to be held on 27 January 2016 by examining the EU statement to be presented on this occasion (doc. WK 7/2016) and discussing the first draft of the UNGASS outcome document. Delegations presented a number of proposals to improve the text. The major concern was the omission of the call for the abolition of the death-penalty for drug related crimes and the lack of stronger risk and harm reduction language in the current text. Also, more ambitious language was required on alternative development, so as to take a step forward.

#### Other issues

The SE and AT delegation reported on the meeting of the Executive Board of the WHO, during which drugs issues were discussed in relation to the approaching UNGASS 2016. Delegations stressed the importance of such discussions at the WHO meetings and the significant role the WHO had in developing public health dimension of drug issues. The Presidency also expressed satisfaction about the involvement of the WHO in the preparation for UNGASS 2016.

5940/16 JV/np 2
DGD 2C **EN** 

Delegations also informed the meeting about side events to be organised at UNGASS 2016. The FR delegation announced that they will organise a side event with SE and WHO on drug prevention, the DE delegation planned to have a number of side events, including on alternative development to be organised with Thailand and UNODC, and the UK delegation intended to organise a side event on new psychoactive substances, making a call for other EU partners to get involved.

The CZ delegation initiated a discussion on guidance on interpreting the UN Drug Conventions, proposing to consider certain operational recommendations in this respect in the UNGASS outcome document.

### 3. Preparation for the 59th CND session

The DE delegation presented a proposal for a CND resolution from Thailand on alternative development and delegations were invited to submit written comments on this resolution.

Delegations further coordinated as regards the international scheduling of new psychoactive substances, on which the vote will be held at the forthcoming 59th CND session in Vienna in March. The representative of the Commission recalled that out of the substances proposed for scheduling at the forthcoming CND session, four were already scheduled at the EU level and the process on 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone ( $\alpha$ -PVP) was ongoing.

The Presidency informed the meeting about the request received for the EU to sponsor a side event organised by the African Union on risk and harm reduction during the 59th CND session in Vienna.

# 4. Proposal to subject new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone $(\alpha\text{-PVP})$ to control measures

Delegations endorsed the above-mentioned draft Council implementing decision as outlined in doc. 5374/16 CORDROGUE 4 SAN 22.

5940/16 JV/np 3
DGD 2C **F.N** 

### 5. AOB

## - National Drug Coordinators meeting

The Presidency informed the meeting about the above-mentioned meeting to be held on 2-3 May 2016 in Amsterdam.

## - Forthcoming elections of the members of the INCB

The DE delegation informed the meeting about the nomination made in the run-up to the above-mentioned elections.